Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Juliann Chmielecki(AstraZeneca (United States)), Jhanelle E. Gray(Moffitt Cancer Center), Ying Cheng, Yuichiro Ohe, Fumio Imamura(Osaka International Cancer Institute), Byoung Chul Cho(Yonsei University), Meng‐Chih Lin(Chang Gung University), Margarita Majem(Hospital de Sant Pau), Riyaz Shah(Maidstone and Tunbridge Wells NHS Trust), Yuri Rukazenkov(AstraZeneca (United Kingdom)), Alexander Todd(AstraZeneca (United Kingdom)), Aleksandra Markovets(AstraZeneca (United States)), J. Carl Barrett(AstraZeneca (United States)), Ryan J. Hartmaier(AstraZeneca (United States)), Suresh S. Ramalingam(Emory University)
Nature Communications
June 1, 2023
10.1038/s41467-023-38999-0
Cited by 6Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis